



The Commission on Macroeconomics and Health – Ten Years On

9 December 2011, 09.00 – 18.00

Chatham House, 10 St James's Square, London SW1Y 4LE

The Commission on Macroeconomics and Health (CMH), appointed by the World Health Organization, analysed the impact of health on development and sought ways in which health-related investments could advance economic growth and equity in developing countries.

This event will serve as a platform to review developments over the last 10 years in major areas covered by the CMH, which reported its findings and recommendations in December 2001. Most importantly the aim is to look forward at how the world can address the major challenges it now faces in sustaining improvements in global health achieved in the last decade and continuing to build on them.

Themes to be examined at the conference include the quantity and quality of international and national financing for health, the challenges of building domestic health financing systems to deliver a basic package of care, and the role of the private sector and trade rules in stimulating innovation and in promoting access to medicines needed in developing countries.

AGENDA

Moderator in Chief: *Richard Horton*, Editor-in-Chief, The Lancet

08.30 – 09.00 Registration; tea & coffee

SESSION 1 | The CMH Report – Ten Years On: Perspectives on the Report and its Impact

09.00 – 10.45

The central thesis of the CMH report is that investing in health is good for economic development. On that basis it recommended massive increases in health spending by governments and donors. It also made recommendations on the configuration of national health services to deliver essential healthcare interventions, on strengthening investment in research and development, and on measures to promote access to medicines by the pharmaceutical industry in concert with international organisations. The opening session provides an opportunity to consider the validity of the report's central propositions and its impact in the light of ten years of unprecedented investment by national governments and donors in health. It also provides an opportunity to highlight the major policy issues in improving health outcomes in the next decade in the light of today's very different circumstances.

Chair: **Dr. Richard Horton**

Open: **Professor David L. Heymann**, Head & Senior Research Fellow, Centre on Global Health Security, Chatham House

Welcome Address: **Hon. Dr. Aaron Motsoaledi**, Minister of Health, Republic of South Africa

Keynote Address: **Professor Jeffrey Sachs**, Director, Earth Institute, Columbia University

Panellists: **Adesina Iluyemi**, *NEPAD Council*, **Dean Jamison** *University of Washington*, **Prabhat Jha** *University of Toronto*, **Mohga Kamal-Yanni** *Oxfam GB*, **Anne Mills** *London School of Hygiene & Tropical Medicine*

Followed by Q&A session

10.45 – 11.15 Break

SESSION 2 | National and International Financing for Health

11.15 - 13.00

The CMH recommended that health spending by national governments should increase by 1% of GNP by 2007 and 2% of GNP by 2015, and that international development assistance for health should increase from \$7 billion in 2001 to \$27 billion in 2007 and \$38 billion in 2015. Each country should set up a national commission to chart its own way forward in the light of its own circumstances. This session reviews the overall record on health financing in the last decade, experiences in establishing national commissions, and that of international financing agencies. The panel discussion will focus on prospects for future financing and the implications for policy.

Chair: **Sir Richard Feachem**, *Director, The Global Health Group, University of California, San Francisco*

Overview: **Dr David Evans**, *Director, Department of Health Systems Financing, WHO*

Panellists: **Nora Lustig**, *Tulane University*, **Sujatha Rao**, *former Indian Government*, **Rifat Atun**, *Global Fund to Fight AIDS, TB & Malaria*, **Alvaro Bermejo** *International HIV/AIDS Alliance*.

Followed by Q&A session

13.00 – 14.00 Lunch

SESSION 3 | Promoting Innovation and Access

14.00 – 15.45

The CMH recommended that at least \$3.0 billion annually should be allocated toward R&D directed at the health priorities of the world's poor and that \$1.5 billion of this should be channelled through a new Global Health Research Fund (GHRF) focussed on basic research and capacity building. On access to medicines the CMH's principal recommendation was that the global community should establish differential pricing in low-income markets as the operational norm and that industry and the international community should jointly agree guidelines on pricing and voluntary licensing of a set of essential medicines in low income markets. This session provides an opportunity to review progress on innovation and access relevant to the world's poor and to consider future policy.

Chair: **Dr Hans Hogerzeil**, *former Director, Essential Medicines and Pharmaceutical Policies, WHO*

Panellists: **Seth Berkley** CEO *GAVI Alliance*, **Jon Pender** *GlaxoSmithKline*, **Dilip Shah** *Indian Pharmaceutical Alliance*, **Martha Gyansa-Latterodt** *Ministry of Health, Ghana*, **Ellen t' Hoen** *Medicines Patent Pool*, **Sophia Tickell** *Meteos*.

Followed by Q&A

15.45 – 16.15 Break

SESSION 4 | Where Do We Go from Here? Priorities for the Next Decade

16.15 – 18.00

A new CMH established now would face a very different world. How would its analysis differ? How would its recommendations differ? What issues could Chatham House address as follow-up to the Conference?

Chair: **Professor David L. Heymann**, *Head & Senior Research Fellow, Centre on Global Health Security, Chatham House*

Panellists: **Gorrik Ooms** *Institute of Tropical Medicine, Antwerp*, **Felicia Knaul** *Harvard Global Equity Initiative*, **Tido von Schoen-Angerer** *MSF Access Campaign*, **Mark Walport**, *Wellcome Trust*, **Dyna Arhin-Tenkorang** *Harvard University*.

Followed by Q&A

Close: **Sir George Alleyne**, *UN Special Envoy for HIV/AIDS, Caribbean*

Please join us for a reception.